The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
iCo Therapeutics Number One in Class in TSX Venture Top 50
Feb. 14, 2013 06:55PM PST
Life Science Investing NewsiCo Therapeutics Inc. (TSXV:ICO) proudly announced that it has been named the number one company in technology and life science in the TSX Venture 50 for 2013.
iCo Therapeutics Inc. (TSXV:ICO) proudly announced that it has been named the number one company in technology and life science in the TSX Venture 50 for 2013.
As quoted in the press release:
Our positive clinical update on our Phase 2 iDEAL study for the treatment of diabetic macular edema was well received by the sector and investment community, which has been demonstrated in our strong and growing performance in 2012,” said Andrew Rae, President and CEO of iCo Therapeutics. “We expect to announce primary endpoint data from the iDEAL study before the end of the year and have several other catalyst events in 2013. We aim to continue our 2012 momentum and hope to make the list again next year.
Click here to read the full iCo Therapeutics Inc. (TSXV:ICO) press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.